EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.

被引：0
|
作者：
Emery, M. G. [1 ]
Gibbs, J. P. [1 ]
Slatter, J. G. [2 ]
Hamilton, L. [3 ]
Wasserman, S. M. [1 ]
Geller, M. [1 ]
Dias, C. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Amgen Inc, Seattle, WA USA
[3] Amgen Ltd, Uxbridge, Middx, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-034
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [41] INCLISIRAN DURABLY LOWERS LDL-C AND PCSK9 EXPRESSION IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: THE ORION-2 PILOT STUDY
    Raal, F.
    Lepor, N.
    Kallend, D.
    Stoekenbroek, R.
    Wijngaard, P.
    Hovingh, G. K.
    ATHEROSCLEROSIS, 2019, 287 : E7 - E7
  • [42] SIRNA TO PCSK9 IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C: THE ORION 1 TRIAL
    Ray, Kausik K.
    Landmesser, Ulf
    Leiter, Lawrence A.
    Kallend, David
    Wijngaard, Peter L. J.
    Wright, R. Scott
    Kastelein, John J. P.
    ATHEROSCLEROSIS, 2017, 263 : E9 - E10
  • [43] ACUTE PROGRESSION OF CORONARY DISEASE ON PCSK9 INHIBITION WITH ELEVATED LP(A) AND CORRECTED LDL-C OF ZERO
    Alam, Loba
    Fishberg, Robert
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 2778 - 2778
  • [44] Relationship Between Baseline PCSK9 and LDL-C Reduction in Response to the Investigational RNAi Therapeutic Inclisiran
    Stoekenbroek, Robert M.
    Kallend, David
    Wijngaard, Peter L.
    Wright, R. Scott
    Landmesser, Ulf
    Leiter, Lawrence A.
    Kastelein, John J.
    Ray, Kauik K.
    CIRCULATION, 2018, 138
  • [45] 姜黄素通过调节PCSK9促进肝细胞摄取血浆LDL-C
    王楚瑶
    蒋素素
    向德彪
    杨慧仙
    邵倞琦
    李博洁
    袁育林
    贺卫和
    张敏
    龙石银
    田英
    张彩平
    廖端芳
    中国药理学通报, 2020, 36 (10) : 1415 - 1421
  • [46] Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy
    Ciric, Milica Zrnic
    Ostojic, Miodrag
    Baralic, Ivana
    Kotur-Stevuljevic, Jelena
    Djordjevic, Brizita I.
    Markovic, Stana
    Zivkovic, Stefan
    Stankovic, Ivan
    NUTRIENTS, 2021, 13 (03) : 1 - 12
  • [47] The Effects of Mild or Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol
    Bui, Khanh
    She, Fahua
    Sostek, Mark
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1368 - 1374
  • [48] CVI-LM001, a First-in-class Novel Oral PCSK9 Modulator, Lowers Plasma Ldl-c and Reduces Circulating PCSK9 in Preclinical Animal Models and in Hyperlipidemic Human Subjects
    Liu, Jingwen
    Jiang, Bo
    Zhao, Shuiping
    Cai, Siyu
    Xiang, Daxiong
    Huang, Minghui
    Fang, Pingfei
    Ran, Zourong
    Chen, Minli
    Shou, Qiyang
    Wang, Jianan
    CIRCULATION, 2020, 142
  • [49] Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic β-cells
    Zhang, Zhiyan
    Zheng, Huadong
    Zhang, Lusha
    Su, Peihong
    Chen, Xiaochang
    Xiang, Aoqi
    Yang, Juan
    Guan, Hua
    Fan, Jianglin
    Yu, Qi
    ISLETS, 2025, 17 (01)
  • [50] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
12345